1.28  0.04 (3.23%)		05-12 16:00
Open: 1.2 High: 1.28 Volume: 496,029		Pre. Close: 1.24 Low: 1.165 Market Cap: 3(M)

Short term
Mid term
Targets	6-month :	2.44	1-year :	3.13
Resists	First :	2.09	Second :	2.68
Pivot price	1.39
Supports	First :	1.14	Second :	0.95
MAs	MA(5) :	1.3	MA(20) :	1.39
	MA(100) :	2.21	MA(250) :	3.29
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	6.9	D(3) :	8.7
RSI	RSI(14): 42.2
52-week	High :	23.79	Low :	1.14

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GLMD ] has closed above bottom band by 30.2%. Bollinger Bands are 18.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.28 - 1.29	1.29 - 1.3
Low:	1.15 - 1.16	1.16 - 1.16
Close:	1.27 - 1.28	1.28 - 1.29

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Tue, 06 May 2025
GLMD: Galmed's Aramchol Boosts Cancer Drug Efficacy in Early Studies | GLMD Stock News - GuruFocus

Tue, 06 May 2025
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire

Mon, 28 Apr 2025
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks

Mon, 28 Apr 2025
Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus

Mon, 28 Apr 2025
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire

Thu, 17 Apr 2025
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	2.9 (%)
Held by Institutions	2 (%)
Shares Short	96 (K)
Shares Short P.Month	49 (K)

EPS	-8.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	9.81
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-22.4 %
Return on Equity (ttm)	-49.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.75
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.16
PEG Ratio	0
Price to Book value	0.13
Price to Sales	0
Price to Cash Flow	-0.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.